ZINZINO AB (PUBL): PRELIMINARY SALES REPORT 2019

Strong sales growth during 2019; total revenue increased with a total of 47% for Q4 and 33% for the full year 2019, compared with the previous year.

The revenue in December for Zinzino's sales markets increased by 84% to MSEK 66.6 (36.1) due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 56% and amounted to MSEK 2.8 (6.3) due to high level of internal production during the month. Overall the Group increased revenues by 64% to MSEK 69.3 (42.4) compared with the previous year.

The fourth quarter of 2019 became the strongest sales quarter in history of the company; the Zinzino based revenue in October-December increased 57% to MSEK 219.9 (140.4). Total revenue increased by 47% to MSEK 230.0 (156.3).  

Accumulated revenue for January – December 2019 increased by 33% MSEK 765.2 (577.1).

Revenues distributed as follows:

The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 15:00 the 13th of January 2020.

    
Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North.